A two-part roundup from Pharma Voice touching on the health department's research timelines and a set of odd side effects being reported on GLP-1 drugs.
Recap by typeshit. Full story at Pharma Voice.
One study cited by @fittrwithsquats put the risk of non-scarring hair loss about 40% higher with GLP-1 use, mostly telogen effluvium. Nail findings are less consistent.
European regulators first raised NAION, a rare optic nerve condition sometimes called an eye stroke, as a possible risk more than 15 months ago.
Obesity doctor Spencer Nadolsky takes on six popular misconceptions about Ozempic in a quick social video. The caption doesn't say which myths are covered.
Users described more appetite, fatigue, extra energy and insomnia. An analysis of Reddit comments, not a clinical trial, so the findings come from self-reports.
JAMA Medical News flags unapproved GLP-1 drugs sold cheaply online, pointing to missing regulation, unknown contents and safety risks.
JAMA flags unapproved GLP-1 drugs sold without regulation, pointing to unknown contents and safety concerns for buyers chasing cheaper shots.
Loading…